• A resource use questionnaire was developed and administered to a sample of Canadian physicians who regularly treat children with lower limb spasticity.
Methods
• A resource use questionnaire was developed and administered to a sample of Canadian physicians who regularly treat children with lower limb spasticity.
• A clinical expert provided guidance during questionnaire design.
• Questionnaire sections included:
• General information (including setting of treatment, measurement scales, treatment goals),
• Use of toxin therapy and use of oral pharmacotherapies,
• Annual frequency of hospitalizations and ambulatory care (including outpatient visits, physiotherapy, and radiology).
• Questionnaire participants were identified through scientific publications, employment with known treatment centers in Canada, and referral from other study participants.
• Physicians were contacted via email with requests to collaborate, and the 30-minute phone questionnaire was administered by a trained researcher.
• Questionnaire results were synthesized and ranges of numerical responses were reported.
Results

Study sample
• Six physicians from pediatric hospitals and rehabilitation centers across Canada completed the questionnaire ( Figure  1 ). All physician respondents treated patients with lower limb spasticity in outpatient clinic settings.
• Medical specialties included orthopedics, pediatrics (including developmental and neurology subspecialties), and pediatric neurosurgery.
Questionnaire results
• General functioning, health related quality of life (HRQoL), and pain were indicated as elements of the patients' condition that were most important to target with spasticity treatment.
• Among pediatric spasticity patients, resource use was reported to differ for unilateral compared to bilateral spasticity, and by baseline gross motor function, as measured by the gross motor functional classification system (GMFCS ; Table 1 ).
• Questionnaire results indicate that pediatric spasticity patients are primarily managed in the outpatient setting. • Hospitalizations for spasticity management are rare, but may occur in this population for other complications of cerebral palsy (e.g. intractable seizures).
• Radiology visits may include annual hip surveillance X-rays.
• Current pharmacotherapies for lower limb spasticity include oral baclofen, (which is more likely to be used in patients with bilateral spasticity and GMFCS IV-V) and botulinum toxin A, including off-label use, as it has historically only been indicated in specific subtypes of lower limb spasticity.
• Lower limb orthopedic surgeries such as hip adductor releases, tendoachilles lengthening, and hamstring lengthening are common in this population.
• Neurosurgeries such as rhizotomy and baclofen pump insertion occur less frequently and among severe cases only.
Effect of toxin therapy on resource use
• There was consensus among clinicians, that toxin use affected overall resource use: 1. Toxin therapy may delay time to orthopedic surgeries, facilitate casting and the use of orthoses, and reduce the number of repeat surgeries required. 
Conclusions
• There is a lack of published evidence describing health resource use for children with lower limb spasticity in Canada.
•These patients are treated primarily in outpatient clinic settings, with high use of physiotherapy.
•Toxin therapy is a common treatment in Canada, despite being used off-label for this indication.
•Anecdotal evidence from Canadian physicians suggests that toxin therapy and continued long-term treatment may allow:
• Reduced oral pharmacotherapies, • A delay to orthopedic surgeries, • Reduced need for outpatient services such as physiotherapy.
